Synairgen stock sinks 85% as COVID-19 treatment misses trial targets
Shares in Synairgen PLC plummeted 85% on Monday after the company said that a Phase 3 trial of its inhaled treatment for Covid-19 failed to meet its primary or key secondary efficacy endpoints.The U.K. drug-discovery company said the treatment, SNG001, a formulation containing the anti-viral protein interferon beta, was administered to 309 patients, with a further 314 receiving a placebo, along with both groups receiving standard care.
Patients who received the treatment were no more likely to leave the hospital or make a full recovery than those who received the placebo. The company said that improvement of the standard of care across the coronavirus pandemic may have compromised the potential of SNG001 to show a clinical benefit.
The trial showed the product was safe and well-tolerated, and there was a secondary endpoint trend in favor of SNG001 reducing progression to severe disease or death within 35 days of treatment compared to a placebo. The company said it will review the full dataset of the trial to understand the results and implications for development.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Covid-19: Five more Covid-related deaths and 2,147 casesThe total number of deaths linked to the virus reported by Stormont's Department of Health is 3,175.
Lire la suite »
U.S. records over 1 million excess deaths from COVID-19; infants with vaccinated mothers less likely to be hospitalized with COVID-19, study suggests: Coronavirus update for Feb. 18, 2022The United States has recorded more than 1 million “excess deaths” during the COVID-19 pandemic, and a new study suggests that infants born of vaccinated mothers less likely to be hospitalized with COVID-19.
Lire la suite »
Province chooses Ontario company over Sask. business for COVID-19 contract | The Star Phoenix
Lire la suite »
Queen Elizabeth II has tested positive for COVID-19Buckingham Palace said the 95-year-old monarch is experiencing mild, cold-like symptoms and will continue with light duties over the next week. She has received three jabs of coronavirus vaccine.
Lire la suite »
Queen Elizabeth II tests positive for COVID-19Earlier this month, Prince Charles, 73, the heir to the throne, contracted COVID\u002D19 for a second time days after meeting the Queen
Lire la suite »